Anticoagulation Management for Cancer-Associated Venous Thromboembolism with Renal Impairment and Abdominal Aortic Aneurysm

Introduction to Anticoagulation Considerations

The American Society of Clinical Oncology recommends considering the risk of bleeding and thrombosis in patients with cancer-associated venous thromboembolism (VTE) and abdominal aortic aneurysm (AAA), particularly in those with moderate renal impairment, as seen in patients with creatinine clearance of 46 mL/min 1, 2, 3, 4

Guidelines define severe renal impairment as creatinine clearance <30 mL/min, where low molecular weight heparin (LMWH) is not preferred, and moderate renal dysfunction requires caution 1, 2, 3, 4

For patients with cancer-associated VTE and moderate renal impairment, direct oral anticoagulants (DOACs) such as edoxaban or rivaroxaban may be preferable to LMWH for long-term treatment, with dose adjustments based on renal function 4, 5, 6
Edoxaban requires dose reduction to 30 mg daily when creatinine clearance is 15-50 mL/min 5
Rivaroxaban 15 mg twice daily for 21 days, then 20 mg daily is an option, with dose reduction to 15 mg daily if creatinine clearance is 15-50 mL/min 5, 6

Platelet count should be monitored every 2-3 days for the first 2 weeks to detect heparin-induced thrombocytopenia if using heparin products 1
Imaging surveillance of AAA should be performed every 3 months 7

Indefinite anticoagulation is indicated for patients with metastatic cancer, with initial treatment lasting at least 6 months 1, 2, 3, 4
Patients with metastatic disease or receiving chemotherapy should continue anticoagulation beyond 6 months, with reassessment of the risk-benefit ratio every 3-6 months 1, 2, 3, 4, 6

Therapeutic anticoagulation is recommended for a minimum of 3 months for upper extremity deep vein thrombosis (DVT) 9
If the DVT is catheter-related, anticoagulation should continue while the catheter remains in place 9

The American Society of Clinical Oncology recommends against using standard LMWH dosing without considering renal function, even in patients with moderate impairment, and suggests alternative agents or dose adjustments 1
Warfarin is inferior to both LMWH and DOACs in cancer-associated VTE and should not be used as first-line treatment 1, 2, 3, 4